home / stock / pcsa / pcsa short
Short Information | Processa Pharmaceuticals Inc. (OTCMKTS:PCSA)
Twenty Trading Day Totals | |
---|---|
Total Shorted Volume | 15,508 |
Total Actual Volume | 22,719 |
Short Trends | |
---|---|
Cover Days | 2 |
Short Days | 14 |
No Change Days | 4 |
Averages | |
---|---|
Average Short Volume | 775 |
Average Short Percentage | 67.47% |
Is there a PCSA Short Squeeze or Breakout about to happen?
See the PCSA Short Analysis for free Sign up or Login
Powered by Squeeze Report
Date | Open | Close | High | Low | Total Volume | Short Volume | Short Percentage |
---|---|---|---|---|---|---|---|
09-23-2020 | $9.99 | $9.94 | $9.99 | $9.74 | 800 | 800 | 100% |
09-22-2020 | $10.1 | $10.1 | $11 | $10.1 | 2,100 | 900 | 42.86% |
09-21-2020 | $8.19 | $9.39 | $9.39 | $8.19 | 2,280 | 2,280 | 100% |
09-18-2020 | $8.19 | $8.39 | $8.39 | $8.19 | 1,600 | 1,600 | 100% |
09-17-2020 | $8 | $8 | $8 | $7.805 | 1,500 | 1,076 | 71.73% |
09-16-2020 | $8.45 | $8.05 | $8.45 | $8.05 | 1,000 | 500 | 50% |
09-14-2020 | $8 | $8.45 | $8.45 | $8 | 1,814 | 820 | 45.2% |
09-08-2020 | $7.7 | $7.6 | $7.7 | $7.6 | 200 | 100 | 50% |
09-03-2020 | $8 | $8 | $8 | $8 | 184 | 180 | 97.83% |
09-02-2020 | $7.95 | $7.95 | $7.95 | $7.95 | 1,050 | 1,000 | 95.24% |
09-01-2020 | $7.9 | $7.9 | $8 | $7.9 | 302 | 2 | 0.66% |
08-27-2020 | $8.15 | $8.25 | $8.25 | $8.15 | 200 | 100 | 50% |
08-21-2020 | $8.19 | $8.19 | $8.19 | $8.19 | 250 | 150 | 60% |
07-22-2020 | $8.5 | $8.5 | $8.5 | $8.5 | 900 | 900 | 100% |
07-17-2020 | $8 | $8 | $8 | $8 | 200 | 200 | 100% |
07-16-2020 | $7 | $8 | $8 | $7 | 805 | 400 | 49.69% |
07-13-2020 | $6.71 | $6.5 | $6.71 | $6.255 | 4,300 | 2,800 | 65.12% |
06-09-2020 | $6.5 | $7 | $7 | $6 | 1,286 | 300 | 23.33% |
05-29-2020 | $8 | $8 | $8 | $8 | 900 | 900 | 100% |
05-13-2020 | $8.01 | $6.0001 | $8.01 | $6.0001 | 1,048 | 500 | 47.71% |
News, Short Squeeze, Breakout and More Instantly...
Processa Pharmaceuticals Inc. Company Name:
PCSA Stock Symbol:
OTCMKTS Market:
Processa Pharmaceuticals (NASDAQ: PCSA) , a clinical-stage pharmaceutical company focused on developing the next generation of chemotherapeutic drugs with improved efficacy and safety, will be represented at this month’s EF Hutton Annual Global Conference. According to the announcement, ke...
HANOVER, Md., May 06, 2024 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) (“Processa” or the “Company”), a clinical-stage pharmaceutical company focused on developing the next generation of chemotherapeutic drugs with improved efficacy and safety, ...
Processa (NASDAQ: PCSA) is a clinical-stage pharmaceutical company focused on developing the next generation of chemotherapeutic drugs with improved efficacy and safety. The company today announced that it has named Steven Cha, M.D. as senior vice president of clinical research. In the newly cre...